AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

CVE:NVHNovoheart Stock Price, Forecast & News

C$0.38
-0.01 (-2.56 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.38
Now: C$0.38
C$0.39
50-Day Range
C$0.37
MA: C$8,802.32
C$440,095.00
52-Week Range
C$0.21
Now: C$0.38
C$0.72
Volume13,500 shs
Average Volume35,301 shs
Market CapitalizationC$71.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States, Canada, and Hong Kong. It offers an array of next-generation human heart tissue prototypes. The company provides a range of bioengineering technologies known as the MyHeart platform, including the human mini-heart 'novoHeart' that is capable of pumping and ejecting fluid. Its MyHeart platform develops cell-based cardiac regenerative therapies. The company's MyHeart products include human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. It also provides screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. The company is based in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-398 3170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$435,659.00
Cash FlowC$0.09 per share
Book ValueC$0.13 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$71.68 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NVH News and Ratings via Email

Sign-up to receive the latest news and ratings for NVH and its competitors with MarketBeat's FREE daily newsletter.

Novoheart (CVE:NVH) Frequently Asked Questions

How has Novoheart's stock been impacted by COVID-19 (Coronavirus)?

Novoheart's stock was trading at C$0.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVH stock has decreased by 41.5% and is now trading at C$0.38. View which stocks have been most impacted by Coronavirus.

Has Novoheart been receiving favorable news coverage?

Media headlines about NVH stock have been trending very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novoheart earned a news sentiment score of -3.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutNovoheart.

Who are some of Novoheart's key competitors?

What other stocks do shareholders of Novoheart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novoheart investors own include InVitae (NVTA) and Natera (NTRA).

Who are Novoheart's key executives?

Novoheart's management team includes the following people:
  • Dr. Ronald Li B.Sc. (Hons), Ph.D., Scientific Co-Founder, CEO & Director (Age 48)
  • Prof. Kevin Costa B.S., Ph.D., Chief Scientific Officer & Scientific Co-Founder (Age 53)
  • Dr. Camie Chan B.S., B.Sc. (Hons), M.Sc., Ph.D., Interim CFO, COO, Corp. Sec. & Director (Age 45)
  • Prof. Michelle Khine, Scientific Co-Founder & Member of Scientific Advisory Board
  • Dr. Bill A. Williams, Sr. VP of Commercial Operations

What is Novoheart's stock symbol?

Novoheart trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NVH."

How do I buy shares of Novoheart?

Shares of NVH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Novoheart's stock price today?

One share of NVH stock can currently be purchased for approximately C$0.38.

How big of a company is Novoheart?

Novoheart has a market capitalization of C$71.68 million and generates C$435,659.00 in revenue each year.

What is Novoheart's official website?

The official website for Novoheart is www.novoheart.com.

How can I contact Novoheart?

The company can be reached via phone at 604-398 3170.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.